Ipsen
Focus: Ipsen is a mid-cap biotechnology company headquartered in Tianjin, China, with 1,001–5,000 employees specializing in small molecules and biologics across oncology, endocrinology, neurology, and gastroenterology. The company generates 73% of revenue from its flagship product AURYXIA, indicating high concentration risk.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Employees
1001-5000
Open Jobs
266+48 this month
Hot — 137 jobs added in 30d
Net +48 (137 new, 89 removed). Aggressive expansion phase.
Should You Work at Ipsen?
AI assessmentIpsen offers near-term career stability and commercial growth, but long-term prospects depend on whether pipeline programs (elafibranor, odevixibat, palovarotene) can offset the imminent AURYXIA cliff.
Why Work Here
- Access to diverse therapeutic areas (oncology, endocrinology, neurology, gastroenterology, metabolic diseases) with active pipeline of 30 programs spanning Phase 1 to Phase 4
Data completeness
6/9 — Partial
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
1 in 5yr
AURYXIA
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$183M Part DStable
Peak
Help build intelligence for Ipsen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.